PE20211976A1 - Composiciones de liberacion retardada de linaclotida - Google Patents

Composiciones de liberacion retardada de linaclotida

Info

Publication number
PE20211976A1
PE20211976A1 PE2021000748A PE2021000748A PE20211976A1 PE 20211976 A1 PE20211976 A1 PE 20211976A1 PE 2021000748 A PE2021000748 A PE 2021000748A PE 2021000748 A PE2021000748 A PE 2021000748A PE 20211976 A1 PE20211976 A1 PE 20211976A1
Authority
PE
Peru
Prior art keywords
linaclotide
delayed release
composition
histidine
coated tablet
Prior art date
Application number
PE2021000748A
Other languages
English (en)
Inventor
Anil Chhettry
Matthew Miller
Ritesh Sanghvi
Mohammad Mafruhul Bari
Andreas Grill
Mahendra Dedhiya
Angelika Fretzen
Mark G Currie
Ahmad Hashash
Yun Mo
Original Assignee
Forest Laboratories Holdings Ltd
Ironwood Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52293217&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20211976(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Forest Laboratories Holdings Ltd, Ironwood Pharmaceuticals Inc filed Critical Forest Laboratories Holdings Ltd
Publication of PE20211976A1 publication Critical patent/PE20211976A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)

Abstract

Esta referido a una composicion de liberacion retardada que comprende una tableta con revestimiento enterico o una capsula de liberacion retardada, donde la tableta de revestimiento enterico comprende: linaclotida; Ca2+; histidina; y polivinilpirrolidona (PVP); y donde el revestimiento enterico comprende: copolimeros de acido metacrilicoacrilato de metilo; acetato succinato de celulosa (CAS); ftalato de hidroxipropilmetilcelulosa (HPMCP); acetato succinato de hidroxipropil metilcelulosa (HPMCAS); ftalato de acetato de polivinilo (PVAP); copolimeros de acido metacrilicometacrilato de metilo; alginato de sodio y acido estearico; goma de guar; o mezclas de los mismos; y la composicion comprende (i) polimero en una relacion molar a linaclotida entre 80:1 y 300:1, (ii) histidina en una relacion molar a linaclotida entre 100:1 y 10:1, y (iii) Ca2+ en una relacion molar a linaclotida entre 60:1 y 30:1. Esta composicion se emplea en el tratamiento del sindrome del intestino irritable con estrenimiento (IBS-c) y el estrenimiento cronico idiopatico (CIC).
PE2021000748A 2013-12-11 2014-12-11 Composiciones de liberacion retardada de linaclotida PE20211976A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361914951P 2013-12-11 2013-12-11
US201361914952P 2013-12-11 2013-12-11
PCT/US2014/069838 WO2015089326A1 (en) 2013-12-11 2014-12-11 Delayed release compositions of linaclotide

Publications (1)

Publication Number Publication Date
PE20211976A1 true PE20211976A1 (es) 2021-10-05

Family

ID=52293217

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2021000748A PE20211976A1 (es) 2013-12-11 2014-12-11 Composiciones de liberacion retardada de linaclotida
PE2016000804A PE20161373A1 (es) 2013-12-11 2014-12-11 Composiciones de liberacion retardada de linaclotida

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2016000804A PE20161373A1 (es) 2013-12-11 2014-12-11 Composiciones de liberacion retardada de linaclotida

Country Status (28)

Country Link
US (7) US20160310560A1 (es)
EP (2) EP3821881A1 (es)
JP (4) JP6964380B2 (es)
KR (3) KR102337809B1 (es)
CN (3) CN115089556A (es)
AU (3) AU2014362220B2 (es)
CA (1) CA2933587C (es)
CL (1) CL2016001424A1 (es)
CY (1) CY1123953T1 (es)
DK (1) DK3079669T3 (es)
EA (1) EA201691216A1 (es)
EC (2) ECSP16059106A (es)
ES (1) ES2838007T3 (es)
HR (1) HRP20201753T1 (es)
HU (1) HUE052981T2 (es)
IL (2) IL246155A0 (es)
LT (1) LT3079669T (es)
MX (2) MX2016007625A (es)
NZ (2) NZ721952A (es)
PE (2) PE20211976A1 (es)
PH (1) PH12016501122A1 (es)
PL (1) PL3079669T3 (es)
PT (1) PT3079669T (es)
RS (1) RS61133B1 (es)
SG (2) SG10201804817TA (es)
SI (1) SI3079669T1 (es)
UA (1) UA119335C2 (es)
WO (2) WO2015089326A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA119335C2 (uk) * 2013-12-11 2019-06-10 Айронвуд Фармасьютикалз, Інк. Композиції лінаклотиду з затриманим вивільненням
WO2016020901A1 (en) 2014-08-07 2016-02-11 Acerta Pharma B.V. Methods of treating cancers, immune and autoimmune diseases, and inflammatory diseases based on btk occupancy and btk resynthesis rate
CA2936746C (en) 2014-10-31 2017-06-27 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
US20180008547A1 (en) * 2015-02-02 2018-01-11 Aurobindo Pharma Ltd Stable Compositions comprising Linaclotide
JP2018516937A (ja) * 2015-06-05 2018-06-28 アイアンウッド ファーマシューティカルズ インコーポレイテッド リナクロチドの改変または標的放出製剤
WO2017156214A1 (en) * 2016-03-11 2017-09-14 Gateway Pharmaceutical LLC Pharmaceutical compositions for colon-specific delivery
US10588864B2 (en) 2016-03-11 2020-03-17 Gateway Pharmaceuticals LLC Pharmaceutical compositions for colon-specific delivery
WO2018065826A1 (en) * 2016-10-06 2018-04-12 Sucampo Ag Multilayer beads for pharmaceutical use
JP2020512292A (ja) * 2016-12-21 2020-04-23 アイアンウッド ファーマシューティカルズ インコーポレイテッド リナクロチドの改変放出製剤または遅延放出製剤による過敏性腸症候群の処置方法
KR102227486B1 (ko) * 2017-06-30 2021-03-12 롯데정밀화학 주식회사 프로톤 펌프 저해제를 포함하는 경구용 고형제제 조성물, 이를 포함하는 경구용 고형제제 및 그 제조방법
CN112188888A (zh) * 2018-03-23 2021-01-05 帕拉丁科技公司 用于胃肠道特异性递送的黑皮质素受体特异性肽配制品和方法
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
EP3979992A4 (en) * 2019-06-10 2023-09-13 Ironwood Pharmaceuticals, Inc. TREATMENT OF ABDOMINAL PAIN ASSOCIATED WITH DIARRHEA-DOMINANT IRGITABLE BOWEL SYSTEM
KR102104507B1 (ko) * 2019-08-23 2020-04-24 브릿지바이오테라퓨틱스(주) 팔미토일-l-프롤릴-l-프롤릴-글리실-l-타이로신 나트륨을 포함하는 약제학적 제제 및 이의 제조방법
CN110935007B (zh) * 2019-12-12 2023-06-23 烟台大学 利那洛肽复方组合物、制剂及其用途和制备方法
WO2022245650A1 (en) * 2021-05-19 2022-11-24 Alberto Paz Orally administered compositions for cancer treatment
WO2024076577A1 (en) * 2022-10-03 2024-04-11 Brim Biotechnology, Inc. Compositions comprising pedf-derived short peptides (pdsp) and uses thereof
WO2024143501A1 (ja) * 2022-12-28 2024-07-04 中外製薬株式会社 分散対象物質を含む固体分散体、それを含む医薬組成物及びそれらの製造方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7304036B2 (en) 2003-01-28 2007-12-04 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7371727B2 (en) 2003-01-28 2008-05-13 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
CN201252259Y (zh) * 2008-07-24 2009-06-03 富士康(昆山)电脑接插件有限公司 电连接器
PL2328601T3 (pl) * 2008-08-15 2020-07-13 Ironwood Pharmaceuticals, Inc. Formulacje zawierające linaklotyd do podawania doustnego
CA2994066A1 (en) * 2008-12-03 2010-06-10 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase c agonists and methods of use
US20130012454A1 (en) * 2009-07-06 2013-01-10 Ironwood Pharmaceuticals, Inc. Orally Disintegrating Compositions of Linaclotide
WO2011017502A2 (en) 2009-08-06 2011-02-10 Ironwood Pharmaceuticals, Inc. Linaclotide-containing formulations for oral administration
WO2011020054A1 (en) * 2009-08-13 2011-02-17 Ironwood Pharmaceuticals Inc. Method for modulating the pharmacodynamic effect of orally administered guanylate cyclase receptor agonists
UA108636C2 (xx) * 2010-02-17 2015-05-25 Пептид
SI2603232T1 (sl) * 2010-08-11 2020-03-31 Ironwood Pharmaceuticals, Inc. Stabilne formulacije linaklotida
CN103702678A (zh) * 2010-09-11 2014-04-02 硬木药品公司 便秘型肠易激综合征的治疗
JP2012155108A (ja) * 2011-01-26 2012-08-16 Kyocera Document Solutions Inc 現像ローラ、現像装置および画像形成装置
JP6312592B2 (ja) * 2011-08-17 2018-04-18 アイアンウッド ファーマシューティカルズ インコーポレイテッド 消化器疾患の治療
BR112014007753B1 (pt) * 2011-09-30 2021-07-06 Astellas Pharma Inc. composição farmacêutica granular, formulação e método para produção
US20140018307A1 (en) * 2012-07-12 2014-01-16 Forest Laboratories Holdings Ltd. Linaclotide compositions
JP6499591B2 (ja) * 2013-02-25 2019-04-10 シナジー ファーマシューティカルズ インコーポレイテッド 結腸洗浄において用いるためのグアニル酸シクラーゼ受容体アゴニスト
UA119335C2 (uk) * 2013-12-11 2019-06-10 Айронвуд Фармасьютикалз, Інк. Композиції лінаклотиду з затриманим вивільненням

Also Published As

Publication number Publication date
LT3079669T (lt) 2020-12-10
EP3079669B1 (en) 2020-09-30
AU2020202319A1 (en) 2020-04-23
JP2021113227A (ja) 2021-08-05
BR112016013419A2 (pt) 2017-09-26
IL246155A0 (en) 2016-07-31
NZ721952A (en) 2022-05-27
PH12016501122A1 (en) 2016-07-18
US20180015139A1 (en) 2018-01-18
ECSP21072161A (es) 2021-11-18
SI3079669T1 (sl) 2021-01-29
PT3079669T (pt) 2020-11-30
KR20160132001A (ko) 2016-11-16
PL3079669T3 (pl) 2021-04-06
HUE052981T2 (hu) 2021-05-28
US20220031802A1 (en) 2022-02-03
AU2014362220B2 (en) 2020-04-30
MX2021011906A (es) 2021-10-26
JP7483656B2 (ja) 2024-05-15
JP2017504590A (ja) 2017-02-09
AU2022201891A1 (en) 2022-04-07
CL2016001424A1 (es) 2017-09-08
EP3079669A1 (en) 2016-10-19
US20240075094A1 (en) 2024-03-07
US20160310560A1 (en) 2016-10-27
KR102509291B1 (ko) 2023-03-14
CN106659687A (zh) 2017-05-10
IL283012A (en) 2021-06-30
JP6964380B2 (ja) 2021-11-10
UA119335C2 (uk) 2019-06-10
NZ759512A (en) 2022-05-27
US20160310559A1 (en) 2016-10-27
PE20161373A1 (es) 2016-12-17
RS61133B1 (sr) 2020-12-31
HRP20201753T1 (hr) 2020-12-25
JP2019073559A (ja) 2019-05-16
EA201691216A1 (ru) 2016-11-30
AU2014362220A1 (en) 2016-06-30
WO2015089335A1 (en) 2015-06-18
WO2015089326A9 (en) 2016-08-04
MX2016007625A (es) 2016-12-09
KR20230039764A (ko) 2023-03-21
WO2015089326A1 (en) 2015-06-18
US20200038476A1 (en) 2020-02-06
ES2838007T3 (es) 2021-07-01
JP2023126475A (ja) 2023-09-07
US20170157200A1 (en) 2017-06-08
CY1123953T1 (el) 2022-03-24
DK3079669T3 (da) 2020-11-02
ECSP16059106A (es) 2017-02-24
CN115089556A (zh) 2022-09-23
SG10201804817TA (en) 2018-07-30
KR20210152588A (ko) 2021-12-15
SG11201604729QA (en) 2016-07-28
CA2933587C (en) 2023-09-26
KR102337809B1 (ko) 2021-12-10
EP3821881A1 (en) 2021-05-19
CA2933587A1 (en) 2015-06-18
AU2020202319B2 (en) 2022-03-24
CN112569199A (zh) 2021-03-30

Similar Documents

Publication Publication Date Title
PE20211976A1 (es) Composiciones de liberacion retardada de linaclotida
AR084610A1 (es) Comprimido de desintegracion oral de lansoprazol
CR20150402A (es) Formulaciones farmacéuticas resistentes a la manipulación indebida
BR112017001456A2 (pt) sistemas de prótese provisória e métodos de utilização dos mesmos
PE20110583A1 (es) Comprimidos de capecitabina de disgregacion rapida
NZ739324A (en) 17-hydroxyprogesterone ester-containing oral compositions and related methods
BR112015014853A2 (pt) Formulação farmacêutica, formulação farmacêutica liofilizada, uso de uma formulação farmacêutica e artigo de manufatura
CL2016003023A1 (es) “compuestos derivados de (bencil-piperazin-1-il)(tetrahidrofuran-carbonil o tetrahidropiran-carbonil) sustituido, moduladores rorg; composición farmacéutica que los comprende; y su uso en el tratamiento de la esclerosis múltiple y espondilitis anquilosante”. pct
WO2014114255A3 (zh) 一种定位速释生物粘附剂及应用
MX2017015840A (es) Composiciones estables modificadoras de reologia.
BR112015023381A2 (pt) composição de liberação imediata de sovaprevir, composição de sovaprevir de 200 mg, núcleo de comprimido de sovaprevir e comprimido de sovaprevir revestido
WO2014111956A3 (en) Sustained release formulations of curcuminoids and method of preparation thereof
AR111786A1 (es) Composiciones de gemcabeno y su uso
RU2012139394A (ru) Комбинированный гемостатический препарат для наружного применения
UY37024A (es) Premezcla y composición farmacéutica para la administración oral de memantina como suspensión permanente o de preparación previa a la administración al paciente y optativamente por sonda de alimentación enteral y procedimientos correspondientes
AR095143A1 (es) Dispersión sólida que comprende cilostazol amorfo y proceso de preparación
PE20151432A1 (es) Formulaciones de lorazepam de liberacion sostenida
BR112016006485A2 (pt) composições de liberação pulsátil revestidas por compressão
NZ722695A (en) Ectoparasite formulation
MX2015011101A (es) Composiciones farmaceuticas de donepezilo que tienen un perfil de disolución in vitro o parámetros farmacocinéticos específicos.
CR20150411A (es) Composiciones farmacéuticas que contienen dexketoprofeno y tramadol
BR112015016322A8 (pt) formulações de liberação controlada de lorazepam
HRP20191493T1 (hr) Oblici doze za oralnu primjenu aktivnih supstanci
JP2014015438A5 (es)
UA87186U (ru) Средство для лечения пародонта и слизистой оболочки полости рта средством, содержащим лидокаина гидрохлорид, в форме стоматологической лекарственной пленки